TY - JOUR
T1 - The Impact of the Fungal Priority Pathogens List on Medical Mycology
T2 - A Northern European Perspective
AU - Arendrup, Maiken Cavling
AU - Armstrong-James, Darius
AU - Borman, Andrew M.
AU - Denning, David W.
AU - Fisher, Matthew C.
AU - Gorton, Rebecca
AU - Maertens, Johan
AU - Martin-Loeches, Ignacio
AU - Mehra, Varun
AU - Mercier, Toine
AU - Price, Jessica
AU - Rautemaa-Richardson, Riina
AU - Wake, Rachel
AU - Andrews, Natalie
AU - Lewis White, P.
N1 - Publisher Copyright:
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
PY - 2024/1
Y1 - 2024/1
N2 - Fungal diseases represent a considerable global health concern, affecting >1 billion people annually. In response to this growing challenge, the World Health Organization introduced the pivotal fungal priority pathogens list (FPPL) in late 2022. The FPPL highlights the challenges in estimating the global burden of fungal diseases and antifungal resistance (AFR), as well as limited surveillance capabilities and lack of routine AFR testing. Furthermore, training programs should incorporate sufficient information on fungal diseases, necessitating global advocacy to educate health care professionals and scientists. Established international guidelines and the FPPL are vital in strengthening local guidance on tackling fungal diseases. Future iterations of the FPPL have the potential to refine the list further, addressing its limitations and advancing our collective ability to combat fungal diseases effectively. Napp Pharmaceuticals Limited (Mundipharma UK) organized a workshop with key experts from Northern Europe to discuss the impact of the FPPL on regional clinical practice.
AB - Fungal diseases represent a considerable global health concern, affecting >1 billion people annually. In response to this growing challenge, the World Health Organization introduced the pivotal fungal priority pathogens list (FPPL) in late 2022. The FPPL highlights the challenges in estimating the global burden of fungal diseases and antifungal resistance (AFR), as well as limited surveillance capabilities and lack of routine AFR testing. Furthermore, training programs should incorporate sufficient information on fungal diseases, necessitating global advocacy to educate health care professionals and scientists. Established international guidelines and the FPPL are vital in strengthening local guidance on tackling fungal diseases. Future iterations of the FPPL have the potential to refine the list further, addressing its limitations and advancing our collective ability to combat fungal diseases effectively. Napp Pharmaceuticals Limited (Mundipharma UK) organized a workshop with key experts from Northern Europe to discuss the impact of the FPPL on regional clinical practice.
KW - WHO fungal priority pathogen list
KW - fungal diagnostics
KW - fungal surveillance
KW - mycology
UR - http://www.scopus.com/inward/record.url?scp=85199399141&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/27df6350-8542-38fd-bd41-74a77bac7d7b/
U2 - 10.1093/ofid/ofae372
DO - 10.1093/ofid/ofae372
M3 - Article
AN - SCOPUS:85199399141
SN - 2328-8957
VL - 11
JO - Open Forum Infectious Diseases
JF - Open Forum Infectious Diseases
IS - 7
M1 - ofae372
ER -
